Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation

Pilcer, Gabrielle; Sebti, Thami; Amighi, Karim

doi:10.1007/s11095-006-9789-4

Cited by 86 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…by mucoadhesion) [102][103][104][105][106][107], and enhanced drug absorption [106,108]. Particle processing can furthermore be used to prevent or retard moisture uptake by hygroscopic drugs [94,109,110], to escape macrophage clearance [111], or, in contrast, to target specifically the alveolar macrophages [112,113], even though the conditions that influence particle uptake by macrophages are still widely unknown [114]. Also, particle coprocessing with hygroscopic excipients, such as sodium chloride and mannitol, to achieve excipient enhanced particle growth may be desired for enhanced deposition in the deep lung [115,116].…”

Section: Formulation Of High-dose Drugsmentioning

confidence: 99%

“…The formulation has to contain the drug particles in the desired aerodynamic size distribution for deposition in the target area. Formulation design may be needed to achieve previously mentioned effects [97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116] or a better product stability. DPI devices need to disperse the formulation effectively into this size distribution, preferably at the lowest possible flow rate within the first 0.5 L (children) or 1 L (adults) of inhaled air to achieve drug distribution over the entire lung.…”

Section: Dpi Design and Pulmonary Drug Deposition And Distributionmentioning

confidence: 99%

See 1 more Smart Citation

Dry powder inhalation: past, present and future

Boer

Hagedoorn

Hoppentocht

et al. 2016

Expert Opinion on Drug Delivery

226

View full text Add to dashboard Cite

Introduction: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers. Areas covered: The consequences of the choices made for early DPI development with respect of efficacy, production costs and safety and the tremendous amount of energy put into understanding and controlling the dispersion performance of adhesive mixtures are discussed. Also newly developed particle manufacturing and powder formulation processes are presented as well as the challenges, objectives, and new tools available for future DPI design. Expert opinion: Improved inhaler design is desired to make DPIs for future applications cost-effective and safe. With an increasing interest in high dose drug delivery, vaccination and systemic delivery via the lungs, innovative formulation technologies alone may not be sufficient. Safety is served by increasing patient adherence to the therapy, minimizing the use of unnecessary excipients and designing simple and self-intuitive inhalers, which give good feedback to the patient about the inhalation maneuver. For some applications, like vaccination and delivery of hygroscopic formulations, disposable inhalers may be preferred. ARTICLE HISTORY

show abstract

Section: Formulation Of High-dose Drugsmentioning

confidence: 99%

Section: Dpi Design and Pulmonary Drug Deposition And Distributionmentioning

confidence: 99%

Dry powder inhalation: past, present and future

Boer

Hagedoorn

Hoppentocht

et al. 2016

Expert Opinion on Drug Delivery

226

View full text Add to dashboard Cite

show abstract

“…New formulations have been developed using solid lipid microparticles that are composed of distearoylphosphatidylcholine and cholesterol, two well-tolerated components physiologically, as a pharmaceutically acceptable filler and/or carrier to improve the deposition of budesonide [222]. The same composition of lipids has also been used for coating drug particles to modify the surface properties of the particles and enhance aerosol generation [223].…”

Section: Alternatives To Lactose In Dry Powder Formulations For Inhalmentioning

confidence: 99%

Lactose characteristics and the generation of the aerosol

Pilcer¹,

Wauthoz²,

Amighi³

2012

Advanced Drug Delivery Reviews

Self Cite

179

113

View full text Add to dashboard Cite

“…Delivering antibiotics through the pulmonary route increases the local drug concentration in the lung, leading to improved local antibacterial effect in lung infections (1,2). In patients with lung infections, such as cystic fibrosis and pneumonia, the reduction of administration frequency (3), dose (4), and duration of inhalation treatment (5) will increase the patient's compliance and adherence to the therapy (6).…”

Section: Introductionmentioning

confidence: 99%

Swellable Ciprofloxacin-Loaded Nano-in-Micro Hydrogel Particles for Local Lung Drug Delivery

El‐Sherbiny

2014

AAPS PharmSciTech

View full text Add to dashboard Cite

ABSTRACT. Incorporation of drug-loaded nanoparticles into swellable and respirable microparticles is a promising strategy to avoid rapid clearance from the lung and achieve sustained drug release. In this investigation, a copolymer of polyethylene glycol grafted onto phthaloyl chitosan (PEG-g-PHCs) was synthesized and then self-assembled with ciprofloxacin to form drug-loaded nanoparticles. The nanoparticles and free drug were encapsulated into respirable and swellable alginate micro hydrogel particles and assessed as a novel system for sustained pulmonary drug delivery. Particle size, morphology, dynamic swelling profile, and in vitro drug release were investigated. Results showed that drug-loaded nanoparticles with size of 218 nm were entrapped into 3.9-μm micro hydrogel particles. The dry nano-in-micro hydrogel particles exhibited a rapid initial swelling within 2 min and showed sustained drug release. Preliminary in vivo pharmacokinetic studies were performed with formulations delivered to rats by intratracheal insufflation. Ciprofloxacin concentrations in plasma and in lung tissue and lavage were measured up to 7 h. The swellable particles showed lower ciprofloxacin levels in plasma than the controlled group (a mixture of lactose with micronized ciprofloxacin), while swellable particles achieved higher concentrations in lung tissue and lavage, indicating the swellable particles could be used for controlling drug release and prolonging lung drug concentrations.

show abstract

Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation

Cited by 86 publications

References 28 publications

Dry powder inhalation: past, present and future

Dry powder inhalation: past, present and future

Lactose characteristics and the generation of the aerosol

Swellable Ciprofloxacin-Loaded Nano-in-Micro Hydrogel Particles for Local Lung Drug Delivery

Contact Info

Product

Resources

About